0000000000471025

AUTHOR

Gudrun Hefner

showing 9 related works from this author

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study

2021

ObjectivesThe aim was to use routine data available at a patient’s admission to the hospital to predict polypharmacy and drug–drug interactions (DDI) and to evaluate the prediction performance with regard to its usefulness to support the efficient management of benefits and risks of drug prescriptions.DesignRetrospective, longitudinal study.SettingWe used data from a large multicentred pharmacovigilance project carried out in eight psychiatric hospitals in Hesse, Germany.ParticipantsInpatient episodes consecutively discharged between 1 October 2017 and 30 September 2018 (year 1) or 1 January 2019 and 31 December 2019 (year 2).Outcome measuresThe proportion of rightly classified hospital epi…

DrugHospitals PsychiatricLongitudinal studymedicine.medical_specialtymedia_common.quotation_subjectHealth informaticslaw.invention03 medical and health sciencesPharmacovigilance0302 clinical medicinelawRisk FactorsGermanyPharmacovigilanceMedicineHumans1723Drug Interactions030212 general & internal medicine1506Longitudinal StudiesMedical prescriptionPsychiatryhealth informaticsmedia_commonRetrospective StudiesPolypharmacyClinical pharmacologyReceiver operating characteristicbusiness.industryRGeneral MedicinePharmacology and Therapeuticspsychiatry030227 psychiatryPharmaceutical PreparationsMedicineclinical pharmacologybusinessBMJ Open
researchProduct

1012 – Evaluation of a risk-scale for anticholinergic side-effects in elderly psychiatric inpatients

2013

Introduction Many commonly prescribed drugs have anticholinergic properties which can induce side-effects e.g. delirium, especially in an ageing brain with increased sensitivity. Risk-assessment before starting therapy may prevent such sideeffects. Objectives We rated anticholinergic pharmacological properties of prescribed medication and compared the theoretical risk with side-effects in clinical practice. Aims The scale should improve the safety of pharmacotherapy in gerontopsychiatry. Methods Based on five publications that considered anticholinergic properties of drugs, a risk-scale was established. Riskpoints for all drugs were summarized to a total score. Patients were selected from T…

medicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classbusiness.industryClinical PracticePsychiatry and Mental healthPharmacotherapyTherapeutic drug monitoringmedicineAnticholinergicDeliriummedicine.symptomPsychiatryPrescribed drugsbusinessEuropean Psychiatry
researchProduct

Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil

2015

BACKGROUND Aiming to verify that therapeutic drug monitoring has the potential to optimize treatment with acetylcholine esterase inhibitors of patients with Alzheimer dementia, this study investigated whether serum concentrations of donepezil are associated with clinical improvement. METHODS Clinical improvement was measured using the clinical global impression (CGI) scale, and donepezil concentrations were measured in serum by a high-performance liquid chromatographic method with spectrophotometric detection. RESULTS In total, 206 serum samples from 106 patients (49.5% female) were retrospectively available for analysis. Patients included were treated under everyday conditions. Their mean …

MaleDrugmedicine.medical_specialtymedia_common.quotation_subjectGastroenterologyPiperidinesAlzheimer DiseaseInternal medicinemental disordersmedicineHumansDonepezilPharmacology (medical)DonepezilAgedRetrospective Studiesmedia_commonPharmacologyDose-Response Relationship DrugReceiver operating characteristicmedicine.diagnostic_testbusiness.industryRetrospective cohort studyAlzheimer dementiaDose–response relationshipTreatment OutcomeTherapeutic drug monitoringIndansClinical Global ImpressionFemaleCholinesterase InhibitorsDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

2021

PURPOSE The aim of this study was to analyze the epidemiology of polypharmacy in hospital psychiatry. Another aim was to investigate predictors of the number of drugs taken and the associated risks of drug-drug interactions and potentially inappropriate medications in the elderly. METHODS Daily prescription data were obtained from a pharmacovigilance project sponsored by the Innovations Funds of the German Federal Joint Committee. RESULTS The study included 47 071 inpatient hospital cases from eight different study centers. The mean number of different drugs during the entire stay was 6.1 (psychotropic drugs = 2.7; others = 3.4). The mean number of drugs per day was 3.8 (psychotropic drugs …

DrugMalemedicine.medical_specialtyEpidemiologymedia_common.quotation_subjectInappropriate Prescribing030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsPharmacovigilanceEpidemiologyMedicineHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRisk factorPsychiatryPotentially Inappropriate Medication Listmedia_commonAgedPolypharmacyPsychiatrybusiness.industryPharmacoepidemiologyHospitalsPsychotropic drugPharmaceutical PreparationsPolypharmacyFemalebusinessPharmacoepidemiology and drug safetyREFERENCES
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

2017

BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor–induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (ID…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyMicroangiopathyThrombotic thrombocytopenic purpuraCognitionHematologyMicroangiopathic hemolytic anemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesImmunology and AllergyMedicineEffects of sleep deprivation on cognitive performanceYoung adultbusinessDepression (differential diagnoses)030215 immunologyCohort studyTransfusion
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients

2018

Abstract Introduction Many antidepressants cause QT prolongation but the classification of cardiac risk of these drugs varies markedly in different published lists. This retrospective study analyzed the correlation of QTc time with amitriptyline and venlafaxine serum level in elderly psychiatric inpatients. Methods Elderly inpatients aged≥65 years for whom venlafaxine or amitriptyline serum level had been measured were selected retrospectively from a therapeutic drug monitoring database and screened for an electrocardiogram measurement at the time of blood withdrawal. The correlation of amitriptyline or venlafaxine serum levels with QTc time was examined by using Pearson’s correlation analy…

MaleDrugmedicine.medical_specialtyDatabases FactualAmitriptylinemedia_common.quotation_subjectVenlafaxineQT intervalElectrocardiography03 medical and health sciences0302 clinical medicineTherapeutic indexPharmacokineticsmedicineHumansPharmacology (medical)Amitriptyline030212 general & internal medicinePsychiatryAgedRetrospective Studiesmedia_commonAged 80 and overInpatientsmedicine.diagnostic_testbusiness.industryVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineAntidepressive AgentsLong QT SyndromePsychiatry and Mental healthTherapeutic drug monitoringFemalebusiness030217 neurology & neurosurgerymedicine.drugPharmacopsychiatry
researchProduct

Elevated risperidone serum concentrations during acute inflammation, two cases

2015

Inflammation-mediated changes in drug metabolism may lead to alterations in the absorption, distribution, and clearance of psychotropic drugs and thus elevate drug levels in blood and lead to intoxications. We report about two patients who developed an up to threefold increase of dose-related serum concentrations of risperidone’s active moiety (risperidone plus 9-hydroxyrisperidone) during acute inflammation indicated by elevated C-reactive protein. The two female patients (aged 56 and 38 years, respectively) had the diagnoses of paranoid schizophrenia and schizoaffective disorder. For both patients, there was a close time-dependent parallel fluctuation of drug levels and C-reactive protei…

Adultmedicine.medical_specialtyParanoid schizophreniaSchizoaffective disorderInflammationPharmacokineticsInternal medicinemedicineHumansDistribution (pharmacology)PsychiatryInflammationSchizophrenia ParanoidRisperidonebiologybusiness.industryCytochrome P450Middle AgedRisperidonemedicine.diseasePsychiatry and Mental healthC-Reactive ProteinEndocrinologyPsychotic DisordersAcute Diseasebiology.proteinFemalemedicine.symptombusinessDrug metabolismAntipsychotic Agentsmedicine.drugThe International Journal of Psychiatry in Medicine
researchProduct